Medline recalls 0.9% Sodium Chloride Injection in 10mL syringes due to incorrect overwrap packaging. This may lead to improper use during IV procedures. Affected lots: 3131591.
“Medline 0:9% Sodium Chloride Injection Recall: Incorrect Overwrap Hazard.” GovInfoNow, updated August 31, 2026. https://govinfonow.com/recall/72057-medline-0-9-sodium-chloride-injection-recall-incorrect-overwrap-hazard. Based on FDA recall #Z-2948-2018 (https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-2948-2018%22&limit=1).
The FDA announced on 2018-02-01 that Medline Industries Inc is recalling Medline 0.9% Sodium Chloride Injection, USP 5 mL in 10 mL Syringe ZR due to packaging with an incorrect overwrap. The recall affects 90,870 units distributed nationwide.
How to tell if you have it
Brand: Medline
Product: Medline 0.9 % Sodium Chloride Injection, USP 5 mL in 10 mL Syringe ZR
Lot #: 3131591
The hazard
The product was packaged with an incorrect overwrap, according to the FDA. The device is intended for flushing IV catheters and IV tubing only.
Context
GovInfoNow's records show Medline Industries Inc has 48 other recalls on record since 2015-09-25. Other recent recalls of similar products include Medline Chest Tube Kit Recalled (2022-07-21), Medline Hand Sanitizer Foam Recall (2021-11-08), and Medline Bedside PICC CDS Kit Recall (2021-10-27). Additional recent actions include Medline recalls of 10mL colored syringes, 10mL Polycarbonate Syringes, and Convenience Kits with Unapproved Syringes, all reported on 2026-02-27.
How to tell if you have this one
Check for the lot number 3131591 on the syringe packaging. The product is a 0.9% Sodium Chloride Injection in 10mL syringes intended for IV catheter flushing.
Brand
Medline
Category
Medical device
Based on the official FDA remedy
What to do — step by step
Check Syringe Packaging
Look for the lot number 3131591 on the syringe packaging to confirm if it is affected.
Where it went and when
Where it was distributed
Distributed nationwide; the notice names 27 states.
Named in the notice
Covered by “nationwide”
Not listed
FDA distribution: “US Nationwide Distribution to states of: CA, CT, DE, FL, GA, IN, LA, MA, MD, MN, MS, NC, NJ, NM, NY, OH, OK, OR, PA, RI, SC, TN, TX, VA, VT, WA and WV” States read from FDA’s own wording; “not listed” means the notice does not name it.
Named in the notice: California, Connecticut, Delaware, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts, Minnesota, Mississippi, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Vermont, Virginia, Washington, West Virginia.
Recall timeline
FDA terminated this recall 2.7 years after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The hazard is related to incorrect overwrap packaging, which could lead to improper handling during IV procedures. However, the risk is low and does not involve immediate danger to users.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #Z-2948-2018 (February 1, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for Z-2948-2018 to see it in context.
Plain-language summary written by qwen3:4b on August 31, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.